Medivation Announces Participation at Upcoming Investor Conference

(firmenpresse) - SAN FRANCISCO, CA -- (Marketwire) -- 03/06/13 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it will present at the following conference:

Patrick Machado, chief business and financial officer, will present at the Barclays Global Healthcare Conference on March 12 at 1:30pm ET in Miami, FL.



Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at .



Patrick Machado
Chief Business & Financial Officer
(415) 829-4101

Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 06.03.2013 - 21:30 Uhr
Sprache: Deutsch
News-ID 236834
Anzahl Zeichen: 0

contact information:
Town:

SAN FRANCISCO, CA

Kategorie:

Biotech

Diese Pressemitteilung wurde bisher 184 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Medivation Announces Participation at Upcoming Investor Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Medivation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Jennifer Jarrett to Join Medivation as Chief Financial Officer ...

SAN FRANCISCO, CA -- (Marketwired) -- 03/28/16 -- Medivation, Inc. (NASDAQ: MDVN) today announced that healthcare investment banking veteran Jennifer Jarrett will join Medivation as its new Chief Financial Officer (CFO) on April 23, 2016, succeeding ...

Pivotal Phase III Trial of Enzalutamide Initiated in Metastatic Hormone Sensitiv ...

SAN FRANCISCO, CA and TOKYO, JAPAN -- (Marketwired) -- 03/24/16 -- Medivation, Inc. (NASDAQ: MDVN) and Astellas Pharma Inc. (TSE: 4503) today announced that the ARCHES ( Inhibition with hemoormonal Therapy in Men with Mtastatic Castrate ensitive Pro ...

U.S. FDA Lifts Partial Clinical Hold on Medivation's Pidilizumab ...

SAN FRANCISCO, CA -- (Marketwired) -- 03/09/16 -- Medivation, Inc. (NASDAQ: MDVN) today announced that the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the Investigational New Drug (IND) application for pidilizumab ...

Alle Meldungen von Medivation